Charles Schwab’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $544K | Sell |
61,503
-18,731
| -23% | -$166K | ﹤0.01% | 3112 |
|
|
2025
Q1 | $863K | Sell |
80,234
-2,055
| -2% | -$22.1K | ﹤0.01% | 2892 |
|
|
2024
Q4 | $1.05M | Buy |
82,289
+24,920
| +43% | +$319K | ﹤0.01% | 2897 |
|
|
2024
Q3 | $1.58M | Sell |
57,369
-7,513
| -12% | -$207K | ﹤0.01% | 2775 |
|
|
2024
Q2 | $1.88M | Buy |
64,882
+911
| +1% | +$26.4K | ﹤0.01% | 2726 |
|
|
2024
Q1 | $2.85M | Buy |
63,971
+628
| +1% | +$28K | ﹤0.01% | 2486 |
|
|
2023
Q4 | $2.46M | Buy |
63,343
+807
| +1% | +$31.3K | ﹤0.01% | 2549 |
|
|
2023
Q3 | $1.84M | Buy |
62,536
+4,936
| +9% | +$145K | ﹤0.01% | 2622 |
|
|
2023
Q2 | $3.66M | Buy |
57,600
+626
| +1% | +$39.8K | ﹤0.01% | 2357 |
|
|
2023
Q1 | $2.69M | Buy |
56,974
+331
| +0.6% | +$15.6K | ﹤0.01% | 2442 |
|
|
2022
Q4 | $3.93M | Buy |
56,643
+1,037
| +2% | +$72K | ﹤0.01% | 2338 |
|
|
2022
Q3 | $8.15M | Buy |
55,606
+31,146
| +127% | +$4.57M | ﹤0.01% | 1950 |
|
|
2022
Q2 | $3.19M | Buy |
24,460
+1,803
| +8% | +$235K | ﹤0.01% | 2388 |
|
|
2022
Q1 | $2.29M | Buy |
22,657
+14,097
| +165% | +$1.42M | ﹤0.01% | 2600 |
|
|
2021
Q4 | $1.33M | Buy |
8,560
+247
| +3% | +$38.3K | ﹤0.01% | 2807 |
|
|
2021
Q3 | $2.46M | Buy |
+8,313
| New | +$2.46M | ﹤0.01% | 2654 |
|